Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORIC 
Oric Pharmaceuticals Inc (ORIC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: ORIC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $18.27
1 Year Target Price $18.27
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.27B USD | Price to earnings Ratio - | 1Y Target Price 18.27 |
Price to earnings Ratio - | 1Y Target Price 18.27 | ||
Volume (30-day avg) 12 | Beta 1.68 | 52 Weeks Range 3.90 - 14.93 | Updated Date 10/26/2025 |
52 Weeks Range 3.90 - 14.93 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.89 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.69% | Return on Equity (TTM) -43.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 820192212 | Price to Sales(TTM) - |
Enterprise Value 820192212 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 97122987 | Shares Floating 63511635 |
Shares Outstanding 97122987 | Shares Floating 63511635 | ||
Percent Insiders 6.71 | Percent Institutions 99.26 |
Upturn AI SWOT
Oric Pharmaceuticals Inc
Company Overview
History and Background
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. Founded in 2014, they aim to improve patient outcomes by targeting mechanisms of therapeutic resistance.
Core Business Areas
- Precision Oncology: Oric focuses on developing small molecule inhibitors targeting key cancer resistance mechanisms. They have multiple drug candidates in clinical development.
Leadership and Structure
The company is led by Jacob Chacko, MD as CEO, along with a team of experienced executives and a board of directors with expertise in drug development and oncology.
Top Products and Market Share
Key Offerings
- ORIC-114 (EGFR/HER2 Inhibitor): An orally bioavailable, potent brain penetrant designed to selectively inhibit EGFR and HER2 with activity against exon 20 insertion mutations. It is currently in Phase 1b trials for EGFR/HER2 mutant cancers. Competitors include other EGFR/HER2 inhibitors from companies like AstraZeneca, Roche, and Novartis. Market share data is not yet available as it is in clinical trials.
- ORIC-533 (Polycomb Repressive Complex 2 (PRC2) Inhibitor): An oral small molecule inhibitor of PRC2, targeting EED, being developed for the treatment of multiple myeloma and other B-cell malignancies. It is in Phase 1 trials. Competitors include other companies developing PRC2 inhibitors. Market share data is not yet available as it is in clinical trials.
- ORIC-944 (Glucocorticoid Receptor (GR) Antagonist): An oral selective GR antagonist designed to target resistance to therapies. It is currently in Phase 1b trials in combination with enzalutamide in metastatic prostate cancer. Competitors include other therapies targeting GR, although specific GR antagonists are less common in this context. Market share data is not yet available as it is in clinical trials.
Market Dynamics
Industry Overview
The oncology market is characterized by high unmet need and intense competition. It's driven by innovation in targeted therapies, immunotherapies, and diagnostics. The market is expected to continue to grow significantly in the coming years.
Positioning
Oric Pharmaceuticals is positioning itself as a leader in developing therapies that address cancer resistance mechanisms. Their focus on precision oncology and novel targets differentiates them from many larger pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be hundreds of billions of dollars. Oric is positioned to capture a portion of this market by developing therapies that overcome resistance to existing treatments. The specific TAM for each of their drug candidates depends on the indications and market penetration achieved.
Upturn SWOT Analysis
Strengths
- Strong scientific leadership team
- Pipeline of innovative drug candidates targeting cancer resistance
- Focus on precision oncology
- Partnerships with leading research institutions
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Relatively small company compared to established pharmaceutical giants
Opportunities
- Potential for breakthrough therapies that address unmet needs in cancer treatment
- Expansion of pipeline through internal research and development or acquisitions
- Partnerships with larger pharmaceutical companies for development and commercialization
- Favorable regulatory environment for innovative cancer therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- AZN
- RO
- NVS
Competitive Landscape
Oric faces significant competition from established pharmaceutical companies with greater resources and broader pipelines. Oric's advantage lies in its focus on novel targets and resistance mechanisms.
Growth Trajectory and Initiatives
Historical Growth: Oric's historical growth has been primarily driven by advancing its pipeline through preclinical and clinical development.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of its drug candidates. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing ORIC-114, ORIC-533, and ORIC-944 through clinical trials, expanding the research and development pipeline, and strengthening partnerships.
Summary
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing therapies to overcome resistance in cancer. While their innovative pipeline and strong scientific team are advantages, they face risks associated with clinical trial outcomes and competition from larger companies. The successful advancement of their drug candidates is crucial for their future growth. They need to look out for clinical trial failures and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Oric Pharmaceuticals' website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data for competitors is estimated and may not be precise. Future results are not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oric Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-04-24 | President, CEO & Director Dr. Jacob M. Chacko M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.oricpharma.com |
Full time employees 128 | Website https://www.oricpharma.com | ||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.